scholarly journals Role of the Cardiophrenic Lymph Node Status After Neoadjuvant Chemotherapy in Primary Advanced Ovarian Cancer

2021 ◽  
Vol 41 (10) ◽  
pp. 5025-5031
Author(s):  
VERONICA LUENGAS-WUERZINGER ◽  
FRIEDERIKE RAWERT ◽  
SABRINA CLAßEN-VON SPEE ◽  
SAHER BARANSI ◽  
ESTHER SCHULER ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Lymph Node ◽  
Neoadjuvant Chemotherapy ◽  
Advanced Ovarian Cancer ◽  
Lymph Node Status ◽  
Node Status

scholarly journals P234 The role of pre-operative CT staging in predicting the sentinel lymph node status

The Breast ◽  
2011 ◽  
Vol 20 ◽  
pp. S55
Author(s):  
S. Khawaja ◽  
A. Huws ◽  
R. Kannan ◽  
H. Sumrien ◽  
Y. Sharaiha ◽  
...  
Keyword(s):  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Lymph Node Status ◽  
Node Status ◽  
Sentinel Lymph Node Status

Prognostic value of axillary lymph node status after neoadjuvant chemotherapy. Results from a multicentre study

2011 ◽  
Vol 47 (8) ◽  
pp. 1186-1192 ◽  
Author(s):  
Nakul Saxena ◽  
Mikael Hartman ◽  
Rezal Aziz ◽  
Elisabetta Rapiti ◽  
Nirmala Bhoo Pathy ◽  
...  
Keyword(s):  
Lymph Node ◽  
Neoadjuvant Chemotherapy ◽  
Multicentre Study ◽  
Axillary Lymph Node ◽  
Prognostic Value ◽  
Lymph Node Status ◽  
Axillary Lymph ◽  
Axillary Lymph Node Status ◽  
Node Status

Use of changes in blood flow PET measurements to predict post-therapy lymph node status among locally advanced breast cancer patients

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 575-575
Author(s):  
D. A. Mankoff ◽  
L. Dunnwald ◽  
J. Gralow ◽  
G. Ellis ◽  
H. Linden ◽  
...  
Keyword(s):  
Blood Flow ◽  
Lymph Node ◽  
Neoadjuvant Chemotherapy ◽  
Primary Tumor ◽  
Tumor Response ◽  
Locally Advanced ◽  
Lymph Node Status ◽  
Tumor Blood Flow ◽  
Node Status ◽  
Post Therapy

575 Background: Response to neoadjuvant therapy in the primary tumor and nodal metastasis predicts benefit to patients as shown in several large clinical trials. We have previously shown that changes in tumor blood flow (BF) measured by [15O]-water PET predict pathologic primary tumor response. We now test whether primary tumor blood flow changes also predict axillary nodal metastases response and post-therapy lymph node status among women with locally advanced breast cancer (LABC) receiving neoadjuvant chemotherapy. Methds: Fifty-five women with a primary diagnosis of LABC underwent dynamic [15O]-water PET scans prior to and at midpoint of neoadjuvant chemotherapy. We evaluated associations between tumor BF changes and pathologic primary tumor response: categorized as complete (CR), partial (PR) or no response (NR). We also assessed the relationship between primary tumor BF changes and post-therapy axillary lymph node status, categorizing the high risk (HR) group as 4+ nodes with extracapsular extension (ECE, n=12) versus the lower risk (LR) group with either fewer than 4+ nodes or without ECE (n=43). Results: The median changes in BF versus tumor response were: CR = -77%, PR = -40%, and, NR = +20% (P = <0.001). For axillary node response, the median BF change among HR patients was +20% versus - 49% among LR patients (P = 0.004). Eight of 17 patients with an increase in tumor blood flow were HR whereas 4/38 patients with decreased tumor blood flow were HR (P = 0.002). Conclusions: Change in primary tumor blood flow over the course of neoadjuvant chemotherapy predicts pathologic response to treatment with a substantial decrease observed among CRs. An increase in primary tumor BF with treatment portends significant residual primary tumor and a nearly 50% chance of very high-risk nodal disease post-therapy. No significant financial relationships to disclose.

scholarly journals Role of Lymphadenectomy During Interval Debulking Surgery Performed After Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer

2021 ◽  
Vol 11 ◽  
Author(s):  
Minjun He ◽  
Yuerong Lai ◽  
Hongyu Peng ◽  
Chongjie Tong
Keyword(s):  
Ovarian Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Residual Disease ◽  
Advanced Ovarian Cancer ◽  
Progression Free Survival ◽  
Debulking Surgery ◽  
Hazard Ratios ◽  
Significant Difference ◽  
Interval Debulking Surgery

ObjectiveThe role of lymphadenectomy in interval debulking surgery (IDS) performed after neoadjuvant chemotherapy (NACT) in advanced ovarian cancer remains unclear. We aimed to investigate the clinical significance of lymphadenectomy in IDS.MethodsWe retrospectively reviewed and analyzed the data of patients with advanced ovarian cancer who underwent NACT followed by IDS.ResultsIn 303 patients receiving NACT-IDS, lymphadenectomy was performed in 127 (41.9%) patients. One hundred and sixty-three (53.8%) patients achieved no gross residual disease (NGRD), and 69 (22.8%) had residual disease &lt; 1 cm, whereas 71 (23.4%) had residual disease ≥ 1cm. No significant difference in progression-free survival (PFS) and overall survival (OS) was observed between the lymphadenectomy group and the no lymphadenectomy group in patients with NGRD, residual disease &lt; 1 cm, and residual disease ≥ 1 cm, respectively. The proportions of pelvic, para-aortic and distant lymph node recurrence were 7.9% (10/127), 4.7% (6/127) and 5.5% (7/127) in the lymphadenectomy group, compared with 5.7% (10/176, P = 0.448), 4.5% (8/176, P = 0.942) and 5.1% (9/176, P = 0.878), respectively, in no lymphadenectomy group. Multivariate analysis identified residual disease ≥ 1 cm [hazard ratios (HR), 4.094; P = 0.008] and elevated CA125 levels after 3 cycles of adjuvant chemotherapy (HR, 2.883; P = 0.004) were negative predictors for OS.ConclusionLymphadenectomy may have no therapeutic value in patients with advanced ovarian cancer underwent NACT-IDS. Our findings may help to better the therapeutic strategy for advanced ovarian cancer. More clinical trials are warranted to further clarify the real role of lymphadenectomy in IDS.

scholarly journals Prognostic role of lymphovascular invasion and lymph node status among breast cancer subtypes

2018 ◽  
Vol 38 (2) ◽  
pp. 54 ◽  
Author(s):  
Jyh-Cherng Yu ◽  
Guo-Shiou Liao ◽  
Huan-Ming Hsu ◽  
Chi-Hong Chu ◽  
Zhi-Jie Hong ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Lymphovascular Invasion ◽  
Breast Cancer Subtypes ◽  
Lymph Node Status ◽  
Prognostic Role ◽  
Cancer Subtypes ◽  
Node Status

scholarly journals Preoperative CT or PET/CT to Assess Pelvic and Para-Aortic Lymph Node Status in Epithelial Ovarian Cancer? A Systematic Review and Meta-Analysis

Diagnostics ◽  
2021 ◽  
Vol 11 (10) ◽  
pp. 1748
Author(s):  
Camille Mimoun ◽  
Roman Rouzier ◽  
Jean Louis Benifla ◽  
Arnaud Fauconnier ◽  
Cyrille Huchon
Keyword(s):  
Systematic Review ◽  
Ovarian Cancer ◽  
Lymph Node ◽  
Diagnostic Accuracy ◽  
Epithelial Ovarian Cancer ◽  
Meta Analysis ◽  
Lymph Node Status ◽  
Node Status ◽  
Pet Ct ◽  
Preoperative Ct

Background: In advanced epithelial ovarian cancer (EOC), the LION trial restricted lymphadenectomy indication to patients with suspect lymph nodes before and during surgery. Preoperative imaging is used to assess lymph node status, and particularly CT and PET/CT. The aim of this systematic review and meta-analysis was to evaluate the diagnostic accuracy of preoperative CT and PET/CT to detect lymph node metastasis (LNM) in patients with EOC; Methods: Databases were searched from January 1990 to May 2019 for studies that evaluated the diagnostic accuracy of preoperative CT and PET/CT to detect LNM in patients with EOC with histology as the gold standard. Pooled diagnostic accuracy was calculated using bivariate random-effects models and hierarchical summary receiver operating curve (HSROC). This study is registered with PROSPERO number CRD42020179214; Results: A total of five studies were included in the meta-analysis: four articles concerned preoperative CT and four articles concerned preoperative PET/CT, involving 106 and 138 patients, respectively. For preoperative CT, pooled sensitivity was 0.47 95% CI [0.20–0.76], pooled specificity was 0.99 95% CI [0.75–1.00] and area under the curve (AUC) of the HSROC was 0.91 95% CI [0.88–0.93]. For preoperative PET/CT, pooled sensitivity was 0.81 95% CI [0.61–0.92], pooled specificity was 0.96 95% CI [0.91–0.99] and AUC of the HSROC was 0.97 95% CI [0.95–0.98]; Conclusions: PET/CT has a very high diagnostic accuracy, especially for specificity, to detect LNM in EOC and should be realized systematically, additionally to CT recommended to evaluate peritoneal spread, in the preoperative staging of patients with an advanced disease.

scholarly journals The role of neoadjuvant chemotherapy in the management of advanced ovarian cancer ingeriatric patients

2016 ◽  
Vol 14 (4) ◽  
pp. 212-221
Author(s):  
Ewelina Kojs-Pasińska ◽  
◽  
Bożena Cybulska-Stopa ◽  
Krzysztof Koper ◽  
Konrad Dziobek ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Advanced Ovarian Cancer
Sign in / Sign up

Export Citation Format

Share Document